4d Molecular Therapeutics Inc Revenue Growth Rates (FDMT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
4d Molecular Therapeutics Inc   (NASDAQ: FDMT)
 

FDMT's Revenue Growth by Quarter and Year

4d Molecular Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FDMT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 3.78
1st Quarter March 3.05
FY 6.83

FDMTs Annual Revenue
4d Molecular Therapeutics Inc 's Revenue in the fiscal year 2025 $ 85.21 millions
4d Molecular Therapeutics Inc 's Revenue in the fiscal year 2024 $ 0.04 millions
4d Molecular Therapeutics Inc 's Revenue in the fiscal year 2023 $ 20.72 millions
4d Molecular Therapeutics Inc 's Revenue in the fiscal year 2022 $ 3.13 millions
4d Molecular Therapeutics Inc 's Revenue in the fiscal year 2021 $ 18.04 millions




FDMT Revenue second quarter 2026 Y/Y Growth Comment
4d Molecular Therapeutics Inc reported Revenue surge of 18805% year on year in the second quarter 2026, to $ 3.78 millions, this is lower than 4d Molecular Therapeutics Inc 's recent average Revenue surge of 450714.56%.

Among companies who have reported second quarter 2026 results in the Biotechnology & Pharmaceuticals industry only one Company has achieved higher year on year Revenue results in the second quarter 2026. While 4d Molecular Therapeutics Inc ' s Revenue doubling of 18805% ranks overall at the positon no. 11 in the second quarter 2026.


FDMT Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - - - -
3rd Quarter September - - - 3940 %
2nd Quarter June 18805 % 100 % -95.83 % 50 %
1st Quarter March 30400 % -66.67 % -90 % -75.41 %
FY   - 212925 % -99.81 % -

Financial Statements
4d Molecular Therapeutics Inc 's second quarter 2026 Revenue $ 3.78 millions FDMT's Income Statement
4d Molecular Therapeutics Inc 's second quarter 2025 Revenue $ 0.02 millions Quarterly FDMT's Income Statement


FDMT Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 94444.44 % - -
3rd Quarter September - 350 % - 8316.67 %
2nd Quarter June 23.97 % 100 % -66.67 % -20 %
1st Quarter March -96.42 % - - -76 %
FY (Year on Year)   - 212925 % -99.81 % -


Back to FDMT Growth rate Comparisons >> Back to FDMT Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #2
Healthcare Sector #5
Overall #11

Revenue Y/Y Growth Statistics
High Average Low
8508900 % 450714.56 % -99.99 %
 
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #2
Healthcare Sector #5
Overall #11
Revenue Y/Y Growth Statistics
High Average Low
8508900 % 450714.56 % -99.99 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

4d Molecular Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
94444.44 % 5061.75 % -96.42 %
(Dec 31 2025)  


FDMT's II. Quarter Q/Q Revenue Comment
4d Molecular Therapeutics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 23.97% quarter on quarter, to $ 3.78 millions.

Within Biotechnology & Pharmaceuticals industry 13 other companies have achieved higher Revenue quarter on quarter growth. While 4d Molecular Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 446.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #14
Healthcare Sector #95
Overall #446
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #14
Healthcare Sector #95
Overall #446
Revenue Q/Q Growth Statistics
High Average Low
94444.44 % 5061.75 % -96.42 %
(Dec 31 2025)  


FDMT's II. Quarter Q/Q Revenue Comment
4d Molecular Therapeutics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 23.97% quarter on quarter, to $ 3.78 millions.

Within Biotechnology & Pharmaceuticals industry 13 other companies have achieved higher Revenue quarter on quarter growth. While 4d Molecular Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 446.


4d Molecular Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 92.01 $ 88.24 $ 85.21 $ 0.12 $ 0.03
Y / Y Revenue Growth (TTM) 278712.12 % 383560.87 % 230194.59 % 566.67 % -99.84 %
Year on Year Revenue Growth Overall Ranking # 1 # 2 # 30 # 3914 # 3963
Seqeuential Revenue Change (TTM) 4.27 % 3.56 % 70907.5 % 263.64 % 43.48 %
Seq. Revenue Growth (TTM) Overall Ranking # 1 # 2 # 30 # 3914 # 3963


Cumulative Revenue growth Comment
Assuming the 4d Molecular Therapeutics Inc 's fiscal year would have ended in Jun 30 2026, 4d Molecular Therapeutics Inc would have reprted above average annual Revenue surge of 278712.12% year on year, of $ 92 millions.
This marks a slow-down of the companys growth trends and from the 383560.87% surge in Mar 31 2026.

In the Healthcare sector 539 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1, from total ranking in previous quarter at 2.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 65
Healthcare Sector # 540
Overall # 3748

Revenue TTM Y/Y Growth Statistics
High Average Low
383560.87 %
 47133.3 %
-99.92 %
(Mar 31 2026)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 100
S&P 500 # 394
Cumulative Revenue growth Comment
Assuming the 4d Molecular Therapeutics Inc 's fiscal year would have ended in Jun 30 2026, 4d Molecular Therapeutics Inc would have reprted above average annual Revenue surge of 278712.12% year on year, of $ 92 millions.
This marks a slow-down of the companys growth trends and from the 383560.87% surge in Mar 31 2026.

In the Healthcare sector 539 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1, from total ranking in previous quarter at 2.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 65
Healthcare Sector # 540
Overall # 3748

Revenue TTM Y/Y Growth Statistics
High Average Low
383560.87 %
47133.3 %
-99.92 %
(Mar 31 2026)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 100
S&P 500 # 394




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
FDMT's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Polomar Health Services, Inc.27,694.64%$ 27,694.636 millions
4d Molecular Therapeutics Inc 25,106.67%$ 25,106.667 millions
Septerna Inc 22,375.63%$ 22,375.630 millions
Vir Biotechnology Inc 19,582.54%$ 19,582.537 millions
Viskase Holdings inc 17,890.22%$ 17,890.220 millions


About 4d Molecular Therapeutics Inc Revenue Growth Rates (FDMT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: 4D Molecular Therapeutics Inc (CIK 1650648).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-349173
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: 4D Molecular Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.